scholarly journals Adjuvant Interferon Gamma in the Management of Multidrug - Resistant Tuberculosis

10.5772/29906 ◽  
2012 ◽  
Author(s):  
Idrian Garca-Garca ◽  
Mara T ◽  
Pedro A ◽  
Roberto Surez-Mndez ◽  
Magalys Valds-Quintana ◽  
...  
Keyword(s):  
Interferon Gamma ◽  
Multidrug Resistant ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Adjuvant Interferon

scholarly journals Interferon-Gamma Improves Macrophages Function against M. tuberculosis in Multidrug-Resistant Tuberculosis Patients

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Taj Ali Khan ◽  
Humaira Mazhar ◽  
Shamim Saleha ◽  
Hamid Nawaz Tipu ◽  
Niaz Muhammad ◽  
...  
Keyword(s):  
Interferon Gamma ◽  
Molecular Mechanisms ◽  
Mononuclear Cells ◽  
Multidrug Resistant ◽  
Human Interferon ◽  
Peripheral Blood Mononuclear ◽  
Infected People ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Mdr Tb

Background. Mycobacterium tuberculosis (M. tuberculosis) that causes tuberculosis (TB) kills millions of infected people annually especially multidrug-resistant tuberculosis (MDR-TB). On infection, macrophages recognize the mycobacteria by toll-like receptor (TLR) followed by phagocytosis and control of mycobacteria. In addition, macrophages also secrete IL-12 to induce IFN-γ production by T, which, in turn, increases the phagocytosis and oxidative burst. Individuals with defects in innate or adaptive immunity exhibit increased susceptibility to M. tuberculosis. Understanding these immunologic mechanisms will help in TB control. We aimed to investigate the immunopathologic mechanisms in MDR-TB and role of recombinant human interferon-gamma (rhIFN-γ). Study Design and Methods. Monocyte-derived macrophages (MDMs) were generated from peripheral blood mononuclear cells of MDR-TB patients and healthy subjects and were investigated for immunologic response by ELISA and flow cytometry. Results. Different functional and molecular anomalies were observed in macrophages. In addition, a defective immune response to M. tuberculosis from the patient’s MDMs was characterized, which in turn improved by pretreatment with rhIFN-γ. Conclusion. This work highlights the fact that rhIFN-γ improves macrophages function against M. tuberculosis and treatment of patients with poor responsiveness to TB therapy may be needed in future to include IFN-γ as adjuvant therapy after the full characterization of pathological and molecular mechanisms in these and in other more multidrug-resistant TB patients.

scholarly journals The Therapeutic potential of interferon-gamma in tuberculosis

ADMET & DMPK ◽  
2022 ◽  
Author(s):  
Svetlana A. Berns ◽  
Julia A. Isakova ◽  
Polina Pekhtereva
Keyword(s):  
Interferon Gamma ◽  
Clinical Efficacy ◽  
Therapeutic Potential ◽  
Therapeutic Option ◽  
Multidrug Resistant ◽  
Recent Experimental Data ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Complex Therapy

Tuberculosis is one of the critical health problems worldwide. The search for ways to improve the results of tuberculosis treatment and overcome drug resistance lies in understanding the pathogenesis of the development of the infectious process. The interferon system, particularly the role of interferon-gamma, has been identified as the main link in the immune response in tuberculosis. The clinical efficacy of interferon-gamma has been studied and evaluated in clinical trials since the end of the last century. There was obtained evidence of the clinical efficacy of interferon-gamma as part of complex therapy. Recent experimental data make it possible to consider interferon-gamma as a promising therapeutic option for the treatment of multidrug-resistant tuberculosis as part of complex therapy worthy of further studies.  

Sign in / Sign up

Export Citation Format

Share Document